The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of tebentafusp (IMCgp100) for treating metastatic or unresectable HLA-A*02:01 positive uveal melanoma.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
For information, we anticipate that the appraisal will now begin during late August 2021 when we will write to you about how you can get involved.